Greenwich LifeSciences, Inc. (GLSI) shareholders
Close on Nov 17, 2026Market cap $274.48MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GLSI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 485,854 | 3.31% | $11.40M | +51,994 | 0.00% |
| Vanguard Capital Management LLC | 278,190 | 1.90% | $6.53M | −20,076 | 0.00% |
| Geode Capital Management, LLC | 168,179 | 1.15% | $3.95M | +12,713 | 0.00% |
| State Street Corp | 143,086 | 0.97% | $3.36M | +9,211 | 0.00% |
| Vanguard Portfolio Management LLC | 80,861 | 0.55% | $1.90M | +21,950 | 0.00% |
| Northern Trust Corp | 80,228 | 0.55% | $1.88M | +5,103 | 0.00% |
| Bank of New York Mellon Corp | 47,900 | 0.33% | $1.12M | +1,377 | 0.00% |
| Vanguard Fiduciary Trust Co | 45,965 | 0.31% | $1.08M | +1,057 | 0.00% |
| Morgan Stanley | 43,447 | 0.30% | $1.02M | +13,620 | 0.00% |
| Goldman Sachs Group Inc | 39,329 | 0.27% | $922.66K | −192 | 0.00% |
| Russell Investments Group, Ltd. | 34,353 | 0.23% | $805.94K | −5,344 | 0.00% |
| Jane Street Group, LLC | 27,694 | 0.19% | $649.70K | New | 0.00% |
| UBS Group AG | 23,409 | 0.16% | $549.18K | +2,293 | 0.00% |
| State Of Wisconsin Investment Board | 22,639 | 0.15% | $531.11K | +2,300 | 0.00% |
| Gsa Capital Partners Llp | 19,543 | 0.13% | $458.00K | New | 0.03% |
| Massachusetts Financial Services Co /Ma/ | 17,922 | 0.12% | $420.45K | New | 0.00% |
| Strs Ohio | 17,800 | 0.12% | $417.59K | +4,100 | 0.00% |
| Charles Schwab Investment Management Inc | 17,098 | 0.12% | $401.12K | +495 | 0.00% |
| Vanguard Global Advisers, LLC | 11,871 | 0.08% | $278.49K | +1,536 | 0.00% |
| Ancora Advisors, LLC | 10,740 | 0.07% | $251.96K | −26,760 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 58 | 2M | 11.5% | 7 / 24 | 15 / 11 | 0M | 0M |
| Q1 2026 | 64 | 2M | 11.7% | 24 / 18 | 12 / 9 | 1M | 0M |
| Q4 2025 | 50 | 1M | 9.0% | 7 / 15 | 18 / 8 | 0M | 0M |
| Q3 2025 | 51 | 1M | 8.3% | 5 / 16 | 14 / 5 | 0M | 0M |
| Q2 2025 | 51 | 1M | 8.4% | 9 / 20 | 11 / 3 | 0M | 0M |
| Q1 2025 | 46 | 1M | 7.9% | 7 / 10 | 13 / 2 | 0M | 0M |
| Q4 2024 | 42 | 1M | 8.0% | 6 / 16 | 6 / 3 | 0M | 0M |
| Q3 2024 | 39 | 1M | 7.8% | 9 / 12 | 8 / 3 | 0M | 0M |
| Q2 2024 | 34 | 1M | 7.0% | 13 / 11 | 5 / 10 | 1M | 0M |
| Q1 2024 | 31 | 1M | 4.5% | 7 / 10 | 5 / 3 | 0M | 0M |
| Q4 2023 | 27 | 1M | 3.7% | 6 / 11 | 4 / 3 | 0M | 0M |
| Q3 2023 | 24 | 1M | 3.7% | 2 / 4 | 9 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
78 funds held GLSI in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GLSI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 199,015 | 1.36% | $4.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 180,681 | 1.23% | $4.24M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 74,349 | 0.51% | $1.00M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 72,268 | 0.49% | $1.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 63,269 | 0.43% | $1.48M | 0.01% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 34,273 | 0.23% | $897.10K | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 33,114 | 0.23% | $866.76K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 32,771 | 0.22% | $857.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 22,686 | 0.15% | $532.21K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 16,211 | 0.11% | $218.85K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 12,325 | 0.08% | $322.61K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 11,706 | 0.08% | $274.62K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 9,629 | 0.07% | $252.04K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,430 | 0.06% | $220.66K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 8,122 | 0.06% | $109.65K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Snehal Patel | CEO and CFO, Director, 10% owner | 8,324,288 | 56.71% | Jul 30, 2026 |
| Frank Joseph Daugherty | Chief Medical Officer, Director | 90,121 | 0.61% | Dec 27, 2024 |
| Jaye Thompson | VP Clinical Reg Affairs | 264,148 | 1.80% | Dec 27, 2024 |
| David McWilliams | Director | 620,301 | 4.23% | Dec 27, 2024 |
| Kenneth Hallock | Director | 794,308 | 5.41% | Dec 27, 2024 |
| Eric Rothe | Director | 313,226 | 2.13% | Dec 27, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 29, 2026 | Buy | +700 | $13.10 | $9.17K | 5,611,402 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 28, 2026 | Buy | +1,500 | $13.59 | $20.39K | 5,610,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 27, 2026 | Buy | +1,500 | $13.62 | $20.43K | 5,609,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 24, 2026 | Buy | +1,100 | $12.88 | $14.17K | 5,607,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 23, 2026 | Buy | +2,500 | $13.14 | $32.85K | 5,606,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 13, 2026 | Buy | +1,800 | $29.83 | $53.69K | 5,604,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 12, 2026 | Buy | +2,900 | $27.54 | $79.87K | 5,602,302 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 31, 2025 | Buy | +4,300 | $21.36 | $91.85K | 5,599,402 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 30, 2025 | Buy | +2,900 | $21.73 | $63.02K | 5,595,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 18, 2025 | Buy | +4,100 | $12.62 | $51.74K | 5,592,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 25, 2025 | Buy | +4,600 | $8.37 | $38.50K | 5,588,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 7, 2025 | Buy | +10,600 | $8.43 | $89.36K | 5,583,502 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 31, 2025 | Buy | +2,300 | $9.26 | $21.30K | 5,572,902 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 25, 2025 | Buy | +3,600 | $9.88 | $35.57K | 5,570,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 17, 2025 | Buy | +5,400 | $8.98 | $48.49K | 5,567,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 7, 2025 | Buy | +3,600 | $9.10 | $32.76K | 5,561,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 4, 2025 | Buy | +5,500 | $8.73 | $48.02K | 5,558,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 10, 2025 | Buy | +2,500 | $12.51 | $31.28K | 5,552,502 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 7, 2025 | Buy | +1,800 | $13.75 | $24.75K | 5,550,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 6, 2025 | Buy | +1,100 | $13.31 | $14.64K | 5,548,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 3, 2025 | Buy | +3,400 | $12.95 | $44.03K | 5,547,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 2, 2025 | Buy | +2,000 | $11.97 | $23.94K | 5,543,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 31, 2024 | Buy | +2,400 | $11.36 | $27.26K | 5,541,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 30, 2024 | Buy | +3,200 | $11.12 | $35.58K | 5,539,302 |
| Jaye Thompson VP Clinical Reg Affairs | Nov 21, 2024 | Buy | +1,000 | $12.91 | $12.91K | 264,148 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 26, 2024 | Buy | +1,500 | $14.63 | $21.95K | 5,536,102 |
| Jaye Thompson VP Clinical Reg Affairs | Aug 12, 2024 | Buy | +800 | $13.85 | $11.08K | 263,148 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 6, 2024 | Buy | +2,000 | $13.81 | $27.62K | 5,534,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 5, 2024 | Buy | +5,500 | $13.18 | $72.49K | 5,532,602 |
| Jaye Thompson VP Clinical Reg Affairs | Aug 2, 2024 | Buy | +1,000 | $15.15 | $15.15K | 262,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 23, 2024 | Buy | +1,500 | $15.89 | $23.84K | 5,527,102 |
| Jaye Thompson VP Clinical Reg Affairs | Jul 18, 2024 | Buy | +1,000 | $16.00 | $16.00K | 261,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jun 13, 2024 | Buy | +174,825 | $14.30 | $2.50M | 5,525,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 1, 2024 | Buy | +3,000 | $19.08 | $57.24K | 5,350,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 22, 2024 | Buy | +2,500 | $19.98 | $49.95K | 5,347,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 20, 2024 | Buy | +1,500 | $17.68 | $26.52K | 5,345,277 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 5, 2024 | Buy | +30,500 | $12.49 | $380.95K | 5,343,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 5, 2024 | Buy | +3,500 | $12.49 | $43.72K | 5,343,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 4, 2024 | Buy | +4,100 | $13.03 | $53.42K | 5,340,277 |
| Snehal Patel CEO and CFO, Director, 10% owner | Feb 16, 2024 | Buy | +10,800 | $11.16 | $120.53K | 5,336,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Feb 15, 2024 | Buy | +12,700 | $11.07 | $140.59K | 5,325,377 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 10, 2023 | Buy | +5,000 | $10.17 | $50.85K | 5,312,677 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 3, 2023 | Buy | +3,500 | $9.11 | $31.88K | 5,307,677 |
| Jaye Thompson VP Clinical Reg Affairs | Oct 27, 2023 | Buy | +500 | $8.57 | $4.29K | 260,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 26, 2023 | Buy | +2,500 | $7.97 | $19.93K | 5,304,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 25, 2023 | Buy | +2,500 | $7.91 | $19.78K | 5,301,677 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 10, 2023 | Buy | +1,000 | $9.07 | $9.07K | 5,299,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 4, 2023 | Buy | +2,000 | $8.63 | $17.26K | 5,298,177 |
| Jaye Thompson VP Clinical Reg Affairs | Sep 26, 2023 | Buy | +600 | $8.71 | $5.23K | 259,848 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 19, 2023 | Buy | +4,000 | $8.95 | $35.80K | 5,296,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 11, 2023 | Buy | +1,000 | $9.48 | $9.48K | 5,292,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 22, 2023 | Buy | +1,000 | $9.97 | $9.97K | 5,291,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 4, 2023 | Buy | +2,000 | $10.55 | $21.10K | 5,290,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 21, 2023 | Buy | +1,000 | $9.20 | $9.20K | 5,288,177 |
| Jaye Thompson VP Clinical Reg Affairs | Jul 13, 2023 | Buy | +250 | $9.49 | $2.37K | 259,248 |
| Snehal Patel CEO and CFO, Director, 10% owner | May 17, 2023 | Buy | +1,000 | $11.69 | $11.69K | 5,287,177 |
| Jaye Thompson VP Clinical Reg Affairs | Apr 28, 2023 | Buy | +250 | $11.22 | $2.81K | 258,998 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 19, 2023 | Buy | +7,000 | $11.10 | $77.70K | 5,286,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 18, 2023 | Buy | +2,000 | $11.12 | $22.24K | 5,279,177 |
| Jaye Thompson VP Clinical Reg Affairs | Apr 11, 2023 | Buy | +1,000 | $11.87 | $11.87K | 258,745 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Greenwich LifeSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,790 shares on Oct 5, 2026 over the last 90 days.
See a number that looks wrong?